{"id":"hs-10374-matched-placebo-tablets","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HS-10374-matched placebo tablets are inert formulations designed to match the appearance, taste, and administration schedule of the active investigational drug HS-10374 to maintain blinding in phase 3 clinical trials. They contain no active pharmaceutical ingredient and serve as the control arm to assess the true efficacy and safety of HS-10374 relative to no treatment effect.","oneSentence":"This is a placebo tablet formulation used as a control comparator in clinical trials of HS-10374.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:45:56.998Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06926582","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque Psoriasis","status":"NOT_YET_RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2025-04-09","conditions":"Psoriasis","enrollment":305},{"nctId":"NCT06672393","phase":"PHASE3","title":"A Study to Confirm Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis","status":"NOT_YET_RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2024-11-04","conditions":"Psoriasis","enrollment":375},{"nctId":"NCT06176508","phase":"PHASE2","title":"Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis","status":"RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2024-02-26","conditions":"Psoriatic Arthritis","enrollment":160},{"nctId":"NCT06077331","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis","status":"UNKNOWN","sponsor":"Hansoh BioMedical R&D Company","startDate":"2023-09-28","conditions":"Psoriasis","enrollment":120},{"nctId":"NCT06033742","phase":"PHASE1","title":"A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2021-11-13","conditions":"Psoriasis","enrollment":84}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1228,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HS-10374-matched placebo tablets","genericName":"HS-10374-matched placebo tablets","companyName":"Hansoh BioMedical R&D Company","companyId":"hansoh-biomedical-r-d-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}